BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 17, Issue 2
  • This Article
Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (7268)
All Articles published online
The chart showing PDF series, HTML series, Figures (1-5) series.
Item 
Count 
PDF533
HTML6201
Figures (1-5)534
 Sum=7268
Jan 14, 2011 (publication date) through Nov 17, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef
For: Liu J, Fu XQ, Zhou W, Yu HG, Yu JP, Luo HS. LY294002 potentiates the anti-cancer effect of oxaliplatin for gastric cancer via death receptor pathway. World J Gastroenterol 2011; 17(2): 181-190 [PMID: 21245990 DOI: 10.3748/wjg.v17.i2.181]
URL: https://www.wjgnet.com/1007-9327/full/v17/i2/181.htm
Number Citing Articles
1
Jennifer W. Harris, Tianyan Gao, B. Mark Evers. Intestinal Tumorigenesis. 2015; : 101 doi: 10.1007/978-3-319-19986-3_4
2
Qianhui Sun, Jingyuan Wu, Guanghui Zhu, Tingting Li, Xiaoyu Zhu, Baoyi Ni, Bowen Xu, Xinyi Ma, Jie Li. Lactate-related metabolic reprogramming and immune regulation in colorectal cancer. Frontiers in Endocrinology 2023; 13 doi: 10.3389/fendo.2022.1089918
3
Ahmad R. Safa, Karen E. Pollok. Targeting the Anti-Apoptotic Protein c-FLIP for Cancer Therapy. Cancers 2011; 3(2): 1639 doi: 10.3390/cancers3021639
4
Zhen Lu, Aman Xu, Xiao Yuan, Kaiwei Chen, Likun Wang, Tao Guo. Anticancer effect of resibufogenin on gastric carcinoma cells through the phosphoinositide 3‑kinase/protein kinase�B/glycogen synthase kinase 3β signaling pathway. Oncology Letters 2018;  doi: 10.3892/ol.2018.8979
5
CHENFEI ZHOU, JUN JI, MIN SHI, LIU YANG, YINGYAN YU, BINGYA LIU, ZHENGGANG ZHU, JUN ZHANG. Suberoylanilide hydroxamic acid enhances the antitumor activity of oxaliplatin by reversing the oxaliplatin-induced Src activation in gastric cancer cells. Molecular Medicine Reports 2014; 10(5): 2729 doi: 10.3892/mmr.2014.2548
6
Leimarembi Devi Naorem, Mathavan Muthaiyan, Ishita Bhattacharyya, Dinakara Rao Ampasala, Amouda Venkatesan. A Theranostic and Precision Medicine Approach for Female-Specific Cancers. 2021; : 31 doi: 10.1016/B978-0-12-822009-2.00002-9
7
Olga Kersy, Shelly Loewenstein, Nir Lubezky, Osnat Sher, Natalie B. Simon, Joseph M. Klausner, Guy Lahat. Omental Tissue-Mediated Tumorigenesis of Gastric Cancer Peritoneal Metastases. Frontiers in Oncology 2019; 9 doi: 10.3389/fonc.2019.01267
8
Guoqiong Lei, Sushun Liu, Xin Yang, Chao He, Ravindran Caspa Gokulan. TRIM29 Reverses Oxaliplatin Resistance of P53 Mutant Colon Cancer Cell. Canadian Journal of Gastroenterology and Hepatology 2021; 2021(1) doi: 10.1155/2021/8870907
9
Giuseppe Siragusa, Laura Tomasello, Carla Giordano, Giuseppe Pizzolanti. Survivin (BIRC5): Implications in cancer therapy. Life Sciences 2024; 350: 122788 doi: 10.1016/j.lfs.2024.122788
10
Duncan Ayers, Alessandro Nasti. Utilisation of Nanoparticle Technology in Cancer Chemoresistance. Journal of Drug Delivery 2012; 2012: 1 doi: 10.1155/2012/265691
11
Guiqin Hou, Qi Zhao, Mengying Zhang, Tianli Fan, Mingyue Liu, Xiaojing Shi, Yandan Ren, Yang Wang, Jiaxu Zhou, Zhaoming Lu. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma. Biomedicine & Pharmacotherapy 2018; 106: 1348 doi: 10.1016/j.biopha.2018.07.075
12
Hui Zhang, Yidan Lin, Minxue Zhuang, Lin Zhu, Yongmei Dai, Mengbo Lin. Screening and identification of CNIH4 gene associated with cell proliferation in gastric cancer based on a large-scale CRISPR-Cas9 screening database DepMap. Gene 2023; 850: 146961 doi: 10.1016/j.gene.2022.146961
13
Feng Qiu, Chun‐hua Shi, Jun Zheng, Yu‐bin Liu. Periostin Mediates the Increased Pro‐Angiogenic Activity of Gastric Cancer Cells under Hypoxic Conditions. Journal of Biochemical and Molecular Toxicology 2013; 27(7): 364 doi: 10.1002/jbt.21498
14
Fusao Sumiyama, Hoang Hai Duong, Hideyuki Matsushima, Kosuke Matsui, Terufumi Yoshida, Hidekazu Yamamoto, Hisashi Kosaka, Mitsugu Sekimoto, Van Khanh Nguyen, Thanh Tung Lai, Takuya Ohigashi, Tomoya O. Akama, Kengo Yoshii, Emiho Oe, Nanami Fujisawa, Mitsuhiro Ebara, Masaki Kaibori. Efficacy of Nanofiber Sheets Incorporating Oxaliplatin in Gastrointestinal Cancer Xenograft Models. Nanomaterials 2025; 15(19): 1524 doi: 10.3390/nano15191524
15
R. Reilly, M. S. Mroz, E. Dempsey, K. Wynne, S. J. Keely, E. F. McKone, C. Hiebel, C. Behl, J. A. Coppinger. Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-06588-z
16
Yue Song, Zhao-xia Li, Xi Liu, Rui Wang, Li-wei Li, Qingyu Zhang. The Wnt/β-catenin and PI3K/Akt signaling pathways promote EMT in gastric cancer by epigenetic regulation via H3 lysine 27 acetylation. Tumor Biology 2017; 39(7): 101042831771261 doi: 10.1177/1010428317712617
17
Yi-Jun Wang, Xiao-Li Xie, Hong-Qun Liu, Hui Tian, Xiao-Yu Jiang, Jiu-Na Zhang, Sheng-Xiong Chen, Ting Liu, Shu-Ling Wang, Xue Zhou, Xiao-Xu Jin, Shi-Mao Liu, Hui-Qing Jiang. Prostaglandin F<sub>2α</sub> synthase promotes oxaliplatin resistance in colorectal cancer through prostaglandin F<sub>2α</sub>-dependent and F<sub>2α</sub>-independent mechanism. World Journal of Gastroenterology 2023; 29(39): 5452-5470 doi: 10.3748/wjg.v29.i39.5452
Write to the Help Desk
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345